Flow Traders U.S.’s Teva Pharmaceuticals TEVA Stock Holding History

Flow Traders U.S.’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$207K	Sell	6,120 -19,588	-76%	-$652K	0.01%	900
2026 Q1	$774K	Buy	25,708 +17,677	+220%	+$569K	0.02%	526
2025 Q4	$251K	Sell	8,031 -11,211	-58%	-$276K	0.01%	761
2025 Q3	$389K	Buy	19,242 +5,033	+35%	+$88.4K	0.02%	676
2025 Q2	$238K	Buy	+14,209	New	+$229K	0.01%	804
2025 Q1	–	Sell	-29,803	Closed	-$657K	–	1292
2024 Q4	$657K	Buy	+29,803	New	+$542K	0.03%	521
2023 Q1	–	Sell	-24,856	Closed	-$227K	–	1114
2022 Q4	$227K	Buy	24,856 +4,000	+19%	+$34.9K	0.01%	600
2022 Q3	$168K	Buy	20,856 +7,383	+55%	+$65.3K	0.01%	743
2022 Q2	$101K	Sell	13,473 -8,095	-38%	-$70.5K	0.01%	751
2022 Q1	$203K	Buy	+21,568	New	+$180K	0.01%	742
2021 Q4	–	Sell	-20,531	Closed	-$200K	–	1096
2021 Q3	$200K	Sell	20,531 -6,297	-23%	-$59K	0.01%	943
2021 Q2	$266K	Buy	26,828 +7,325	+38%	+$77.5K	0.01%	775
2021 Q1	$225K	Buy	+19,503	New	+$224K	0.01%	738
2020 Q4	–	Sell	-18,552	Closed	-$167K	–	769
2020 Q3	$167K	Buy	+18,552	New	+$196K	0.01%	495
2020 Q2	–	Sell	-47,070	Closed	-$423K	–	549
2020 Q1	$423K	Buy	47,070 +16,879	+56%	+$173K	0.02%	283
2019 Q4	$296K	Buy	30,191 +15,285	+103%	+$136K	0.03%	243
2019 Q3	$103K	Buy	+14,906	New	+$114K	0.01%	327
2019 Q1	–	Sell	-25,711	Closed	-$396K	–	406
2018 Q4	$396K	Buy	25,711 +8,154	+46%	+$167K	0.02%	220
2018 Q3	$378K	Buy	+17,557	New	+$408K	0.04%	190
2018 Q2	–	Sell	-15,436	Closed	-$264K	–	254
2018 Q1	$264K	Buy	+15,436	New	+$301K	0.02%	193
2017 Q3	–	Sell	-8,053	Closed	-$268K	–	261
2017 Q2	$268K	Buy	+8,053	New	+$249K	0.02%	188
2017 Q1	–	Sell	-16,771	Closed	-$608K	–	506
2016 Q4	$608K	Buy	16,771 +9,180	+121%	+$367K	0.04%	195
2016 Q3	$349K	Sell	7,591 -4,089	-35%	-$213K	0.03%	187
2016 Q2	$587K	Buy	11,680 +9,720	+496%	+$517K	0.05%	132
2016 Q1	$105K	Buy	+1,960	New	+$115K	0.01%	172
2015 Q4	–	Sell	-9,153	Closed	-$517K	–	273
2015 Q3	$517K	Buy	+9,153	New	+$593K	0.13%	71
2015 Q1	–	Sell	-15,267	Closed	-$878K	–	220
2014 Q4	$878K	Buy	+15,267	New	+$851K	0.1%	73
2014 Q3	–	Sell	-9,671	Closed	-$507K	–	215
2014 Q2	$507K	Buy	+9,671	New	+$494K	0.09%	65

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Flow Traders U.S.'s TEVA Position: Q2 2026 in Review

Flow Traders U.S. reduced its Teva Pharmaceuticals (TEVA) stake by 76% in Q2 2026, selling an estimated $652K and leaving 6,120 shares worth $207K. The position accounts for 0.01% of the portfolio, ranked #900.

Flow Traders U.S. first reported a position in TEVA in Q2 2014 and has held it in 28 quarters since. The position peaked at $878K in Q4 2014. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Flow Traders U.S. held 6,120 shares of Teva Pharmaceuticals worth $207K as of Q2 2026.
Flow Traders U.S. sold 19,588 Teva Pharmaceuticals shares in Q2 2026, an estimated $652K.
Teva Pharmaceuticals made up 0.01% of Flow Traders U.S.'s portfolio in Q2 2026, its #900 holding.
Flow Traders U.S. first reported a position in Teva Pharmaceuticals in Q2 2014 and has held it in 28 quarters since.
Flow Traders U.S.'s Teva Pharmaceuticals position peaked at $878K in Q4 2014.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Flow Traders U.S.'s 13F filing for Q2 2026, filed 14 Aug 2026.